This review synthesizes current mechanistic insights and clinical evidence regarding GM-CSF and GM-CSFR inhibition in RA, with the aim of critically assessing the therapeutic potential of targeting this pathway as an innovative strategy for durable immune modulation and improved disease control. Here, CSF2RA is linked to rheumatoid arthritis.